
MMSI Stock Forecast & Price Target
MMSI Analyst Ratings
Bulls say
Merit Medical Systems is executing well on its strategy and is expected to continue with strong revenue growth, margin improvement, and free cash flow. The recent acquisition of View Point Medical complements MMSI's portfolio and adds a new growth driver, while the company's Continued Growth Initiatives (CGI) program is expected to drive improved operating margins and cash flow. Strong quarterly results, with revenue and EPS beating consensus, demonstrate MMSI's strong performance and potential for upside in future earnings.
Bears say
Merit Medical Systems is projected to experience only moderate organic revenue growth of 6-8%, due to potential risks such as worse-than-expected margin performance and slower growth in China. While recent acquisitions and new product launches may improve operating margin and lead to positive earnings in line with consensus, the company's stock may only reach $90 based on a P/E multiple of 20.0x. Even in the bull case scenario with organic revenue growth of 9% or higher, the stock is only projected to reach $99 based on a P/E multiple of ~22x and there are still risks to consider such as worse-than-expected margin performance and free cash flow.
This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.
MMSI Analyst Forecast & Price Prediction
Start investing in MMSI
Order type
Buy in
Order amount
Est. shares
0 shares